膀胱尿路上皮癌HER2表达及临床病理分析  

Analysis HER2 expression and clinicopathologic analysis in urothelial carcinoma of the bladder

作　　者：尹玉[1,2] 仲坤 李雪[1,3] 罗文武[1] 蒋俊兰 YIN Yu;ZHONG Kun;LI Xue;LUO Wenwu;JIANG Junlan(Department of Pathology,the First Affiliated Hospital of Anhui Medical University,Hefei 230022,China;Department of Pathology,School of Basic Medical Sciences,Anhui Medical University,Hefei 230032,China;Department of Pathology,the First Affiliated Hospital of Anhui University of Science and Technology,Huainan 232007,China)

机构地区：[1]安徽医科大学第一附属医院病理科,合肥230022 [2]安徽医科大学基础医学院病理学教研室,合肥230032 [3]安徽理工大学第一附属医院病理科,淮南232007

出　　处：《临床与实验病理学杂志》2024年第4期380-385,共6页Chinese Journal of Clinical and Experimental Pathology

摘　　要：目的探讨膀胱尿路上皮癌(bladder urothelial carcinoma,BUC)中HER2的表达情况,并分析其临床意义。方法收集膀胱非浸润性低级别BUC 27例、非浸润性高级别BUC 5例、浸润性高级别BUC 60例,采用免疫组化MaxVision法法检测各组织样本中HER2蛋白的表达,并分析HER2表达与临床病理特征的关系。通过GEPIA数据库或直接在肿瘤基因组图谱(The Cancer Genome Atlas,TCGA)中分析HER2(ERBB2)表达与BUC的关系。结果浸润性高级别BUC中HER22+/3+表达率(26.67%,16/60)显著高于非浸润性低级别BUC(7.41%,2/27)和非浸润性高级别BUC(0,0/5)(P<0.05)。多灶性浸润性高级别BUC中HER22+/3+表达率(75.00%,6/8)显著高于单灶性患者(19.23%,10/52)(P<0.05)。各组织学亚型中HER22+/3+表达率差异有统计学意义(P<0.05),其中普通型为30%(6/20)、腺样分化型为57.14%(4/7)、微乳头型为66.67%(4/6)、浆细胞样型为100.00%(2/2),余亚型均为0/1+。HER2表达与其他临床病理特征均无明显相关性(P>0.05)。GEPIA数据库中,BUC肿瘤组织中HER2(ERBB2)表达高于正常组织(P>0.05),HER2(ERBB2)高表达患者的总生存期(overall survival,OS)低于HER2(ERBB2)低表达(P>0.05);对TCGA数据进行Cox单因素分析显示:年龄、分期、T和N越高的患者OS较短。结论浸润性高级别BUC中HER22+/3+表达率高于非浸润性低级别和高级别BUC,并与肿瘤个数、组织学亚型密切相关,提示结合HER2表达状态、肿瘤个数和组织学亚型或有助于筛选出可能从HER2靶向治疗中获益的浸润性高级别BUC患者。Purpose To investigate the protein expression of human epidermal growth factor receptor 2(HER2)in bladder urothelial carcinoma(BUC)tissues and to analyze its clinical significance.Methods 27 cases of non-invasive low-grade BUC,5 cases of non-invasive high-grade BUC and 60 cases of invasive high-grade BUC of the bladder were collected.The immunohistochemical method(IHC)detection technique was used to detect the expression of HER2 protein in each tissue sample and analyze the relationship between the expression of HER2 and clinicopathological characteristics of BUC.The relationship between HER2(ERBB2)expression and BUC was analyzed indirectly through the GEPIA database or directly in the TCGA(The Cancer Genome Atlas).Results The HER22+/3+expression rate of invasive high-grade BUC(26.67%,16/60)was significantly higher than non-invasive low-grade BUC(7.41%,2/27)and non-invasive high-grade BUC(0,0/5)(P<0.05).The 2+/3+expression rate of HER2 of multifocal invasive high-grade BUC was 75.00%(6/8),which was significantly higher than that of unifocal invasive high-grade BUC,which was 19.23%(10/52)(P<0.05).There was a significant difference in the expression of HER2 in the histological subtypes(P<0.05),with the 2+/3+positive rate of the usual type being 30%(6/20),with adenoid differentiation type was 57.14%(4/7),micropapillary type was 66.67%(4/6),plasma cell-like type was 100.00%(2/2),and the rest of the subtypes were negatively expressed.There was no statistically significant relationship between HER2 expression and other clinicopathologic features(P>0.05).In the TGGA data,HER2(ERBB2)expression in BUC tumor tissues was higher than that in normal tissues(P>0.05),and the overall survival(OS)of patients with high HER2(ERBB2)expression was lower than that of patients with low HER2(ERBB2)expression(P>0.05);the results of the Cox univariate analysis showed that OS was shorter in patients with higher age,Stage,T and N.The above significantly different factors were included in Cox multifactorial analysis,which showed that age,Sta

关 键 词：膀胱尿路上皮癌 浸润性高级别尿路上皮癌 HER2 临床病理 免疫组织化学 

分 类 号：R737.14[医药卫生—肿瘤]